Boundless Bio snags $105m Series B

Boundless Bio, a next-generation precision oncology company, has secured $105 million in Series B financing.

To view this content, you need to sign in.

You should only be asked to sign in once. Not the case? Click here

Register now to access this content and more for free.

Share this